GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases

Hendarto, Hari; Inoguchi, Toyoshi; Maeda, Yasutaka; Ikeda, Noriko; Zheng, Jing; Takei, Ryoko; Yokomizo, Hisashi; Hirata, Eiichi; Sonoda, Noriyuki; Takayanagi, Ryoichi

doi:10.1016/j.metabol.2012.03.002

Cited by 232Chronic Kidney Disease and DiabetesDiabetes Treatment and ManagementNitric Oxide and Endothelin Effects

GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases

Open access

Hendarto, Hari, Inoguchi, Toyoshi, Maeda, Yasutaka, Ikeda, Noriko, Zheng, Jing, Takei, Ryoko, Yokomizo, Hisashi, Hirata, Eiichi +2 more·2012·Metabolism

DOI 10.1016/j.metabol.2012.03.002

Open this paper in CoChat — free account

Abstract

Accumulating evidence has implicated that GLP-1 may have a beneficial effect on cardiovascular and renal diseases but the mechanism is not fully understood. Here we show that GLP-1 analog, liraglutide, inhibits oxidative stress and albuminuria in streptozotocin (STZ)-induced type 1 diabetes mellitus rats, via a protein kinase A (PKA)-mediated inhibition of renal NAD(P)H oxidases. Diabetic rats were randomly treated with subcutaneous injections of liraglutide (0.3 mg/kg/12 h) for 4 weeks. Oxidative stress markers (urinary 8-hydroxy-2'-deoxyguanosine and renal dihydroethidium staining), expression of renal NAD(P)H oxidase components, transforming growth factor-β (TGF-β), fibronectin and urinary albumin excretion were measured. In vitro effect of liraglutide was evaluated using cultured renal mesangial cells. Administration of liraglutide did not affect plasma glucose levels or body weights in STZ diabetic rats, but normalized oxidative stress markers, expression of NAD(P)H oxidase components, TGF-β, fibronectin in renal tissues and urinary albumin excretion, all of which were significantly increased in diabetic rats. In addition, in cultured renal mesangial cells, incubation with liraglutide for 48 h inhibited NAD(P)H-dependent superoxide production evaluated by lucigenin chemiluminescence in a dose-dependent manner. This effect was reversed by both PKA inhibitor H89 and adenylate cyclase inhibitor SQ22536, but not by Epac2 inhibition via its small interfering RNA. Liraglutide may have a direct beneficial effect on oxidative stress and diabetic nephropathy via a PKA-mediated inhibition of renal NAD(P)H oxidase, independently of a glucose-lowering effect.

Integrity signals

Registry

Crossref · 10.1016/j.metabol.2012.03.002

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Liraglutide inhibited NOX4 enzymatic activity in human mesangial cells, and this effect could be blocked by incubation with a protein kinase inhibitor or an adenylate cyclase inhibitor.
“Liraglutide inhibited NOX4 enzymatic activity, and this effect could be blocked by incubation with a protein kinase inhibitor or an adenylate cyclase inhibitor (62).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [62]
Early preclinical studies demonstrated attenuation of renal TGF-β expression in association with reduced expression of collagens within the kidney after GLP-1 receptor agonist therapy.
“Indeed, early preclinical studies demonstrated attenuation of renal TGF-β expression in association with reduced expression of collagens within the kidney after GLP-1 receptor agonist therapy (62).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [62]

Role of Oxidative Stress in Development of Complications in Diabetes
Baynes, J. (1991) · Diabetes · doi:10.2337/diab.40.4.405 · Cited by 3,791 · see citing works
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · see citing works
High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells
Inoguchi, T., Li, P., Umeda, F., Yu, H. Y., Kakimoto, M., Imamura, M., Aoki, T., Etoh, T., Hashimoto, T., Naruse, M., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.11.1939 · Cited by 1,577 · see citing works
Self-citation
Mechanisms Underlying Endothelial Dysfunction in Diabetes Mellitus
Hink, U., Li, H., Mollnau, H., Oelze, M., Matheis, E., Hartmann, M., Skatchkov, M. P., Thaiss, F., Stahl, R. A. K., Warnholtz, A., et al. (2001) · Circulation Research · doi:10.1161/01.res.88.2.e14 · Cited by 1,176 · see citing works
Free radicals and diabetes
Oberley, L. W. (1988) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(88)90036-6 · Cited by 1,105 · see citing works
Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · see citing works
Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · see citing works
Identification of Renox, an NAD(P)H oxidase in kidney
Geiszt, M., Kopp, J. B., Várnai, P., & Leto, T. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.130135897 · Cited by 840 · see citing works
Nox proteins in signal transduction
Brown, D., & Griendling, K. K. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.07.023 · Cited by 822 · see citing works
Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 705 · see citing works
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680 · see citing works
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.
Bose, A. K., Mocanu, M., Carr, R. D., Brand, C. L., & Yellon, D. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 642 · see citing works
Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/endo.137.7.8770921 · Cited by 618 · see citing works
GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · see citing works
Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548 · see citing works
Validation of Lucigenin (Bis-N-methylacridinium) as a Chemilumigenic Probe for Detecting Superoxide Anion Radical Production by Enzymatic and Cellular Systems
Li, Y., Zhu, H., Kuppusamy, P., Roubaud, V., Zweier, J. L., & Trush, M. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.4.2015 · Cited by 526 · see citing works
Nox4 NAD(P)H Oxidase Mediates Hypertrophy and Fibronectin Expression in the Diabetic Kidney
Gorin, Y. C., Block, K. L., Hernandez, J., Bhandari, B., Wagner, B., Barnes, J. L., & Abboud, H. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502412200 · Cited by 497 · see citing works
Glucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men
Gutzwiller, J.-P., Tschopp, S., Bock, A., Zehnder, C. E., Huber, A. R., Kreyenbuehl, M., Gutmann, H., Drewe, J., Henzen, C., Goeke, B., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031403 · Cited by 442 · see citing works
Protein Kinase C–Dependent Increase in Reactive Oxygen Species (ROS) Production in Vascular Tissues of Diabetes: Role of Vascular NAD(P)H Oxidase
Inoguchi, T., Sonta, T., Tsubouchi, H., Etoh, T., Kakimoto, M., Sonoda, N., Sato, N., Sekiguchi, N., Kobayashi, K., Sumimoto, H., et al. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000077407.90309.65 · Cited by 435 · see citing works
Self-citation
Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes
Kodera, R., Shikata, K., Kataoka, H. U., Takatsuka, T., Miyamoto, S., Sasaki, M., Kajitani, N., Nishishita, S., Sarai, K., Hirota, D., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-2028-x · Cited by 394 · see citing works
Epac: A New cAMP-Binding Protein in Support of Glucagon-Like Peptide-1 Receptor-Mediated Signal Transduction in the Pancreatic β-Cell
Holz, G. G. (2004) · Diabetes · doi:10.2337/diabetes.53.1.5 · Cited by 392 · see citing works
Effects of NADPH oxidase inhibitor in diabetic nephropathy
Asaba, K., Tojo, A., Onozato, M. L., Goto, A., Quinn, M. T., Fujita, T., & Wilcox, C. S. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00287.x · Cited by 296 · see citing works
The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice
Rolin, B. C., Larsen, M. O., Gotfredsen, C. F., Deacon, C. F., Carr, R. D., Wilken, M., & Knudsen, L. B. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00030.2002 · Cited by 281 · see citing works
Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment
Etoh, T., Inoguchi, T., Kakimoto, M., Sonoda, N., Kobayashi, K., Kuroda, J., Sumimoto, H., & Nawata, H. (2003) · Diabetologia · doi:10.1007/s00125-003-1205-6 · Cited by 253 · see citing works
Self-citation
Glucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005
Holst, J. J. (2006) · Diabetologia · doi:10.1007/s00125-005-0107-1 · Cited by 228 · see citing works
Long-Term Treatment of Glucagon-Like Peptide-1 Analog Exendin-4 Ameliorates Diabetic Nephropathy through Improving Metabolic Anomalies in db/db Mice
Park, C. W., Kim, H. W., Ko, S. H., Lim, J. H., Ryu, G. R., Chung, H. W., Han, S. W., Shin, S. J., Bang, B. K., Breyer, M. D., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006070778 · Cited by 218 · see citing works
Accumulation of 8-Hydroxy-2′-Deoxyguanosine and Mitochondrial DNA Deletion in Kidney of Diabetic Rats
Kakimoto, M., Inoguchi, T., Sonta, T., Hai, Y., Imamura, M., Etoh, T., Hashimoto, T., & Nawata, H. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1588 · Cited by 208 · see citing works
Self-citation
Translocation of Glomerular p47phox and p67phox by Protein Kinase C-β Activation Is Required for Oxidative Stress in Diabetic Nephropathy
Kitada, M., Koya, D., Sugimoto, T., Isono, M., Araki, S., Kashiwagi, A., & Haneda, M. (2003) · Diabetes · doi:10.2337/diabetes.52.10.2603 · Cited by 204 · see citing works
GLP‐1 derivative liraglutide in rats with β‐cell deficiencies: influence of metabolic state on β‐cell mass dynamics
Sturis, J., Gotfredsen, C. F., Rømer, J., Rolin, B. C., Ribel, U., Brand, C. L., Wilken, M., Wassermann, K., Deacon, C. F., Carr, R. D., et al. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705397 · Cited by 203 · see citing works
Quercetin inhibits inducible ICAM-1 expression in human endothelial cells through the JNK pathway
Kobuchi, H., Roy, S., Sen, C. K., Nguyen, H. G., & Packer, L. (1999) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1999.277.3.c403 · Cited by 197 · see citing works
Vascular NADH Oxidase Is Involved in Impaired Endothelium-Dependent Vasodilation in OLETF Rats, a Model of Type 2 Diabetes
Kim, Y. K., Lee, M.-S., Son, S. M., Kim, I. J., Lee, W. S., Rhim, B. Y., Hong, K. W., & Kim, C. D. (2002) · Diabetes · doi:10.2337/diabetes.51.2.522 · Cited by 157 · see citing works
Bilirubin and biliverdin protect rodents against diabetic nephropathy by downregulating NAD(P)H oxidase
Fujii, M., Inoguchi, T., Sasaki, S., Maeda, Y., Zheng, J., Kobayashi, K., & Takayanagi, R. (2010) · Kidney International · doi:10.1038/ki.2010.265 · Cited by 154 · see citing works
Self-citation
DNA damage in the kidneys of diabetic rats exhibiting microalbuminuria
Ha, H., Kim, C., Son, Y., Chung, M.-H., & KyungHwanKim (1994) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(94)90152-x · Cited by 120 · see citing works
Activation of Jun N-terminal Kinase/Stress-activated Protein Kinase Pathway by Tumor Necrosis Factor α Leads to Intercellular Adhesion Molecule-1 Expression
Cesaris, P. D., Starace, D., Starace, G., Filippini, A., Stefanini, M., & Elio Ziparo, A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.41.28978 · Cited by 102 · see citing works
NAD(P)H Oxidase Activation: A Potential Target Mechanism for Diabetic Vascular Complications, Progressive β-Cell Dysfunction and Metabolic Syndrome
Inoguchi, T., & Nawata, H. (2005) · Current Drug Targets · doi:10.2174/1389450054021927 · Cited by 101 · see citing works
Self-citation
NADPH Oxidase Activation Increases the Sensitivity of Intracellular Ca2+ Stores to Inositol 1,4,5-Trisphosphate in Human Endothelial Cells
Hu, Q., Zheng, G., Zweier, J. L., Deshpande, S., Irani, K., & Ziegelstein, R. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000381200 · Cited by 100 · see citing works
Protein Kinase A Downregulates the Phosphorylation of p47 Phox in Human Neutrophils: A Possible Pathway for Inhibition of the Respiratory Burst
Bengis-Garber, C., & Gruener, N. (1996) · Cellular Signalling · doi:10.1016/0898-6568(96)00052-6 · Cited by 93 · see citing works
Ets-1 Is a Critical Transcriptional Regulator of Reactive Oxygen Species and p47 phox Gene Expression in Response to Angiotensin II
Ni, W., Zhan, Y., He, H., Maynard, E., Balschi, J. A., & Oettgen, P. (2007) · Circulation Research · doi:10.1161/circresaha.107.152439 · Cited by 83 · see citing works
ets‐1 is transcriptionally up‐regulated by H 2 O 2 via an antioxidant response element
Wilson, A., Gemin, A., Espiritu, R., & Singh, G. (2005) · The FASEB Journal · doi:10.1096/fj.05-4401fje · Cited by 80 · see citing works
Statin attenuates high glucose-induced and diabetes-induced oxidative stress in vitro and in vivo evaluated by electron spin resonance measurement
Tsubouchi, H., Inoguchi, T., Sonta, T., Sato, N., Sekiguchi, N., Kobayashi, K., Sumimoto, H., Utsumi, H., & Nawata, H. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.03.031 · Cited by 61 · see citing works
Self-citation
Biliverdin protects against the deterioration of glucose tolerance in db/db mice
Ikeda, N., Inoguchi, T., Sonoda, N., Fujii, M., Takei, R., Hirata, E., Yokomizo, H., Zheng, J., Maeda, Y., Kobayashi, K., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2197-2 · Cited by 54 · see citing works
Self-citation
Signal Transduction of PACAP and GLP-1 in Pancreatic β Cellsa
Leech, C. A., Holz, G. G., & Habener, J. F. (2006) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb17475.x · Cited by 42 · see citing works
Cross-talk between protein kinase C and protein kinase a down-regulates the respiratory burst in polymorphonuclear leukocytes
Savitha, G., & Salimath, B. P. (1993) · Cellular Signalling · doi:10.1016/0898-6568(93)90063-r · Cited by 19 · see citing works

Flagged first, then by citations

Sorted by citations

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407 · see citing works
Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy
Rayego‐Mateos, S., Morgado‐Pascual, J. L., Opazo-Ríos, L., Guerrero‐Hue, M., García‐Caballero, C., Vázquez‐Carballo, C., Mas, S., Sanz, A. B., Herencia, C., Mezzano, S. A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113798 · Cited by 342 · see citing works
The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential
Fujita, H., Morii, T., Fujishima, H., Sato, T., Shimizu, T., Hosoba, M., Tsukiyama, K., Narita, T., Takahashi, T., Drucker, D. J., et al. (2014) · Kidney International · doi:10.1038/ki.2013.427 · Cited by 336 · see citing works
Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction
Groop, P., Cooper, M. E., Perkovic, V., Emser, A., Woerle, H., & von Eynatten, M. (2013) · Diabetes Care · doi:10.2337/dc13-0323 · Cited by 293 · see citing works
Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
Mosenzon, O., Leibowitz, G., Bhatt, D. L., Cahn, A., Hirshberg, B., Wei, C., Im, K., Rozenberg, A., Yanuv, I., Stahre, C., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0621 · Cited by 267 · see citing works
Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1: Incretin actions beyond the pancreas
Seino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 247 · see citing works
A review of the molecular mechanisms of hyperglycemia‐induced free radical generation leading to oxidative stress
Yaribeygi, H., Atkin, S., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27164 · Cited by 226 · see citing works
Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men
Skov, J., Dejgaard, A., Frøkiær, J., Holst, J. J., Jonassen, T., Rittig, S., & Christiansen, J. S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3855 · Cited by 228 · see citing works
Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling
Oh, Y., & Jun, H.-S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010026 · Cited by 217 · see citing works
“The author demonstrated that PKA-mediated inhibition of renal NADPH oxidase was involved in protecting against diabetic nephropathy in STZ-induced diabetic rats [121].”
Background
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00367-2 · Cited by 193 · see citing works
Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association
Rangaswami, J., Bhalla, V., de Boer, I. H., Staruschenko, A., Sharp, J. A., Singh, R. R., Lo, K. B., Tuttle, K., Vaduganathan, M., Ventura, H., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000920 · Cited by 192 · see citing works
Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
Winiarska, A., Knysak, M., Nabrdalik, K., Gumprecht, J., & Stompór, T. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910822 · Cited by 195 · see citing works
The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?
Muskiet, M. H. A., Smits, M. M., Morsink, L. M., & Diamant, M. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.272 · Cited by 182 · see citing works
Glucagon-Like Peptide-1 Receptor Agonist Inhibits Asymmetric Dimethylarginine Generation in the Kidney of Streptozotocin-Induced Diabetic Rats by Blocking Advanced Glycation End Product–Induced Protein Arginine Methyltranferase-1 Expression
Ojima, A., Ishibashi, Y., Matsui, T., Maeda, S., Nishino, Y., Takeuchi, M., Fukami, K., & Yamagishi, S.-I. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.09.016 · Cited by 156 · see citing works
DPP-4 Inhibition on Top of Angiotensin Receptor Blockade Offers a New Therapeutic Approach for Diabetic Nephropathy
Alter, M., Ott, I. M., von Websky, K., Tsuprykov, O., Sharkovska, Y., Relle, K., Raila, J., Henze, A., Klein, T., & Hocher, B. (2012) · Kidney & Blood Pressure Research · doi:10.1159/000341487 · Cited by 150 · see citing works
Short‐term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial
Skov, J., Pedersen, M., Holst, J. J., Madsen, B., Goetze, J. P., Rittig, S., Jonassen, T., Frøkiær, J., Dejgaard, A., & Christiansen, J. S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12651 · Cited by 128 · see citing works
GLP-1 receptor agonists in diabetic kidney disease: from clinical outcomes to mechanisms
Kawanami, D., & Takashi, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00967 · Cited by 129 · see citing works
Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals
Marques, C., Mega, C., Gonçalves, A., Rodrigues-Santos, P., Teixeira-Lemos, E., Teixeira, F., Fontes-Ribeiro, C., Reis, F., & Fernandes, R. (2014) · Mediators of Inflammation · doi:10.1155/2014/538737 · Cited by 126 · see citing works
The potential for renoprotection with incretin-based drugs
Tanaka, T., Higashijima, Y., Wada, T., & Nangaku, M. (2014) · Kidney International · doi:10.1038/ki.2014.236 · Cited by 122 · see citing works
Therapeutic Advances in Diabetic Nephropathy
Sawaf, H., Thomas, G., Taliercio, J. J., Nakhoul, G., Vachharajani, T. J., & Mehdi, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11020378 · Cited by 120 · see citing works
Liraglutide Reduces Oxidative Stress and Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Study
Rizzo, M., Abate, N., Chandalia, M., Rizvi, A. A., Giglio, R. V., Nikolic, D., Marino Gammazza, A., Barbagallo, I., Isenovic, E. R., Banach, M., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2291 · Cited by 113 · see citing works
<scp>GLP</scp> ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
Ryan, D., & Acosta, A. (2015) · Obesity · doi:10.1002/oby.21107 · Cited by 112 · see citing works
Diabetes, hypertension, and chronic kidney disease progression: role of DPP4
Nistala, R., & Savin, V. J. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00316.2016 · Cited by 105 · see citing works
Stromal cell–derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy
Takashima, S., Fujita, H., Fujishima, H., Shimizu, T., Sato, T. K., Morii, T., Tsukiyama, K., Narita, T., Takahashi, T., Drucker, D. J., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.06.012 · Cited by 105 · see citing works
GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways
Aronis, K. N., Chamberland, J. P., & Mantzoros, C. S. (2013) · Metabolism · doi:10.1016/j.metabol.2013.04.010 · Cited by 104 · see citing works
The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes
Thomas, M. C. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30069-1 · Cited by 105 · see citing works
Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes
Kodera, R., Shikata, K., Takatsuka, T., Oda, K., Miyamoto, S., Kajitani, N., Hirota, D., Ono, T., Usui, H. K., & Makino, H. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.12.049 · Cited by 101 · see citing works
New therapeutic targets in chronic kidney disease progression and renal fibrosis
Rayego‐Mateos, S., & Valdivielso, J. M. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1762173 · Cited by 102 · see citing works
Liraglutide prevents cognitive decline in a rat model of streptozotocin-induced diabetes independently from its peripheral metabolic effects
Palleria, C., Leo, A., Andreozzi, F., Citraro, R., Iannone, M., Spiga, R., Sesti, G., Constanti, A., Sarro, G. D., Arturi, F., et al. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.01.004 · Cited by 99 · see citing works
Effects of glucagon-like peptide-1 receptor agonists on renal function
Filippatos, T. D., & Elisaf, M. S. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i5.190 · Cited by 97 · see citing works
Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in J apanese patients with type 2 diabetes: a 26‐week randomized phase III study
Miyagawa, J., Odawara, M., Takamura, T., Iwamoto, N., Takita, Y., & Imaoka, T. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12534 · Cited by 98 · see citing works
GLP-1 mimetics and cognition.
Yaribeygi, H., Rashidy-Pour, A., Atkin, S. L., Jamialahmadi, T., & Sahebkar, A. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118645 · Cited by 96 · see citing works
Antioxidative potential of antidiabetic agents: A possible protective mechanism against vascular complications in diabetic patients
Yaribeygi, H., Butler, A. E., Barreto, G. E., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27278 · Cited by 96 · see citing works
Nox4 as a novel therapeutic target for diabetic vascular complications
Wang, D., Li, J., Luo, G., Zhou, J., Wang, N., Wang, S., Zhao, R., Cao, X., Ma, Y., Liu, G., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102781 · Cited by 96 · see citing works
Accelerated Kidney Aging in Diabetes Mellitus
Guo, J., Zheng, H., Zhang, W., Lou, W., Xia, C., Han, X. T., Huang, W. J., Zhang, F., Wang, Y., & Liu, W. J. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/1234059 · Cited by 99 · see citing works
Effects of GLP-1 in the Kidney
Skov, J. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9287-7 · Cited by 94 · see citing works
Liraglutide Ameliorates Erectile Dysfunction via Regulating Oxidative Stress, the RhoA/ROCK Pathway and Autophagy in Diabetes Mellitus
Yuan, P., Ma, D., Gao, X., Wang, J., Li, R., Liu, Z., Wang, T., Wang, S., Liu, J., & Liu, X. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01257 · Cited by 93 · see citing works
GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
Yu, J. H., Park, S. Y., Lee, D. Y., Kim, N. H., & Seo, J. A. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.22.001 · Cited by 93 · see citing works
Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome
Birnbaum, Y., Bajaj, M., Qian, J., & Ye, Y. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000227 · Cited by 84 · see citing works
The Role of Oxidative Stress in the Pathogenesis of Diabetic Vascular Complications
Sasaki, S., & Inoguchi, T. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.4.255 · Cited by 83 · see citing works
Self-citation
Microinflammation in the pathogenesis of diabetic nephropathy
Shikata, K., & Makino, H. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12050 · Cited by 80 · see citing works
Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells
Toshinobu, M. A. K. I., Maeno, S., Maeda, Y., Yamato, M., Sonoda, N., Ogawa, Y., Wakisaka, M., & Inoguchi, T. (2019) · Scientific Reports · doi:10.1038/s41598-019-41253-7 · Cited by 78 · see citing works
Self-citation
Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists
Prattichizzo, F., de Candia, P., & Ceriello, A. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154799 · Cited by 76 · see citing works
Glucose-responsive hydrogel enhances the preventive effect of insulin and liraglutide on diabetic nephropathy of rats
Tong, M., Luo, L.-Z., Xue, P., Han, Y.-H., Wang, L., Zhuge, D., Yao, Q., Chen, B., Zhao, Y., & Xu, H. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.01.007 · Cited by 72 · see citing works
Exendin-4 attenuates renal tubular injury by decreasing oxidative stress and inflammation in streptozotocin-induced diabetic mice
Sancar-Bas, S., Gezginci-Oktayoglu, S., & Bolkent, S. (2015) · Growth Factors · doi:10.3109/08977194.2015.1125349 · Cited by 71 · see citing works
Novel Insights into the Roles and Mechanisms of GLP-1 Receptor Agonists against Aging-Related Diseases
Peng, W., Zhou, R., Sun, Z., Long, J.-W., & Gong, Y.-Q. (2022) · Aging and Disease · doi:10.14336/ad.2021.0928 · Cited by 73 · see citing works
Mechanistic insights into the effects of quercetin and/or GLP-1 analogue liraglutide on high-fat diet/streptozotocin-induced type 2 diabetes in rats
Gaballah, H. H., Zakaria, S. S., Mwafy, S. E., Tahoon, N., & Ebeid, A. M. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.086 · Cited by 70 · see citing works
Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury
Higashijima, Y., Tanaka, T., Yamaguchi, J., Tanaka, S., & Nangaku, M. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00590.2014 · Cited by 69 · see citing works
The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice
Li, P., Liu, L.-F., Jou, M., & Wang, H. (2016) · BMC Neuroscience · doi:10.1186/s12868-016-0272-9 · Cited by 69 · see citing works
Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes
Ninčević, V., Kolarić, T. O., Roguljić, H., Kizivat, T., Smolić, M., & Bilić-Čurčić, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235831 · Cited by 69 · see citing works
Therapeutic potential of pro-resolving mediators in diabetic kidney disease
Vartak, T., Godson, C., & Brennan, E. P. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113965 · Cited by 67 · see citing works
Endoplasmic Reticulum Stress in the Diabetic Kidney, the Good, the Bad and the Ugly
Cunard, R. A. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4040715 · Cited by 67 · see citing works
Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae212 · Cited by 70 · see citing works
Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy
Hasan, A. A., & Hocher, B. (2017) · Journal of Molecular Endocrinology · doi:10.1530/jme-17-0005 · Cited by 64 · see citing works
Physiology and pathophysiology of incretins in the kidney
von Websky, K., Reichetzeder, C., & Hocher, B. (2013) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000437542.77175.a0 · Cited by 62 · see citing works
The neuroprotection of liraglutide on diabetic cognitive deficits is associated with improved hippocampal synapses and inhibited neuronal apoptosis
Yan, W., Pang, M., Yu, Y., Gou, X., Si, P., Zhawatibai, A., Zhang, Y., Zhang, M., Guo, T., Yi, X., et al. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116566 · Cited by 62 · see citing works
Review of glucagon‐like peptide‐1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects
Sloan, L. A. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12969 · Cited by 60 · see citing works
Clinical therapeutic strategies for early stage of diabetic kidney disease
Kitada, M. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i3.342 · Cited by 57 · see citing works
Association Between Urinary Albumin Excretion and Low-density Lipoprotein Heterogeneity Following Treatment of Type 2 Diabetes Patients with the Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin: A Pilot Study
Tani, S., Nagao, K., & Hirayama, A. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0043-2 · Cited by 56 · see citing works
Liraglutide and sitagliptin counter beta- to alpha-cell transdifferentiation in diabetes
Tanday, N., Flatt, P. R., Irwin, N., & Moffett, R. C. (2020) · Journal of Endocrinology · doi:10.1530/joe-19-0451 · Cited by 56 · see citing works
Improvements of ambient hyperglycemia and glycemic variability are associated with reduction in oxidative stress for patients with type 2 diabetes
Ohara, M., Nagaike, H., Goto, S., Fukase, A., Tanabe, Y., Tomoyasu, M., Yamamoto, T., Hayashi, T., Fukui, T., & Hirano, T. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.017 · Cited by 55 · see citing works
Incretin actions beyond the pancreas: lessons from knockout mice
Yabe, D., & Seino, Y. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.013 · Cited by 53 · see citing works
Liraglutide treatment improves the coronary microcirculation in insulin resistant Zucker obese rats on a high salt diet
Sukumaran, V., Tsuchimochi, H., Sonobe, T., Waddingham, M. T., Shirai, M., & Pearson, J. T. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01000-z · Cited by 52 · see citing works
Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group
Janež, A., Muzurović, E. M., Bogdański, P., Czupryniak, L., Fábryová, Ľ., Fras, Z., Guja, C., Haluzı́k, M., Kempler, P., Lalic, N. M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01615-5 · Cited by 53 · see citing works
Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A
Ishibashi, Y., Matsui, T., Ojima, A., Nishino, Y., Nakashima, S., Maeda, S., & Yamagishi, S. (2012) · Microvascular Research · doi:10.1016/j.mvr.2012.06.008 · Cited by 52 · see citing works
Advances in understanding and treating diabetic kidney disease: focus on tubulointerstitial inflammation mechanisms
Xu, C., Ha, X., Yang, S., Tian, X., & Jiang, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1232790 · Cited by 54 · see citing works
Liraglutide ameliorates renal injury in streptozotocin-induced diabetic rats by activating endothelial nitric oxide synthase activity via the downregulation of the nuclear factor-κB pathway
Zhou, S., Bai, L., Lv, L., Chen, R., Li, C., LIU, X.-Y., Yu, D. M., & Yu, P. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2555 · Cited by 51 · see citing works
Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis
Gaspari, T. A., Brdar, M., Lee, H. W., Spizzo, I., Hu, Y., Widdop, R. E., Simpson, R. W., & Dear, A. E. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115605000 · Cited by 49 · see citing works
β-Glucans (Saccharomyces cereviseae) Reduce Glucose Levels and Attenuate Alveolar Bone Loss in Diabetic Rats with Periodontal Disease
Silva, V. D. O., Lobato, R. V., Andrade, E. F., de Macedo, C. G., Clemente‐Napimoga, J. T., Napimoga, M. H., Messora, M. R., Murata, R. M., & Pereira, L. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134742 · Cited by 48 · see citing works
Liraglutide Reduces Both Atherosclerosis and Kidney Inflammation in Moderately Uremic LDLr-/- Mice
Bisgaard, L. S., Bosteen, M. H., Fink, L. N., Sørensen, C. M., Rosendahl, A., Mogensen, C., Rasmussen, S. E., Rolin, B. C., Nielsen, L. B., & Pedersen, T. X. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168396 · Cited by 47 · see citing works
Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial
Antonsen, K. K., Klausen, M. K., Brunchmann, A., Dous, N. L., Jensen, M. E., Miskowiak, K. W., Fisher, P. M., Thomsen, G. K., Rindom, H., Fahmy, T. P., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-019562 · Cited by 47 · see citing works
The Role of Mitochondria in Diabetic Kidney Disease and Potential Therapeutic Targets
Takasu, M., Kishi, S., Nagasu, H., Kidokoro, K., Brooks, C. R., & Kashihara, N. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.10.035 · Cited by 46 · see citing works
Exendin-4-Loaded PLGA Microspheres Relieve Cerebral Ischemia/Reperfusion Injury and Neurologic Deficits through Long-Lasting Bioactivity-Mediated Phosphorylated Akt/eNOS Signaling in Rats
Chien, C., Jou, M., Cheng, T.-Y., Yang, C., Yu, T., & Li, P.-C. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.126 · Cited by 46 · see citing works
Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence
Kawanami, D., Matoba, K., Sango, K., & Utsunomiya, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081223 · Cited by 46 · see citing works
Liraglutide ameliorates early renal injury by the activation of renal FoxO1 in a type 2 diabetic kidney disease rat model
Chen, P., Shi, X., Xu, X., Lin, Y., Shao, Z., Wu, R., & Huang, L. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.09.006 · Cited by 45 · see citing works
Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria
Haluzı́k, M., Frolík, J., & Rychlík, I. (2013) · International Journal of Endocrinology · doi:10.1155/2013/895102 · Cited by 44 · see citing works
Incretin-Based Therapy for Prevention of Diabetic Vascular Complications
Mima, A. (2015) · Journal of Diabetes Research · doi:10.1155/2016/1379274 · Cited by 44 · see citing works
Liraglutide suppresses production of extracellular matrix proteins and ameliorates renal injury of diabetic nephropathy by enhancing Wnt/β-catenin signaling
Huang, L., Lin, T., Shi, M., Chen, X., & Wu, P. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00128.2020 · Cited by 44 · see citing works
MicroRNAs and their delivery in diabetic fibrosis
Wonnacott, A., Denby, L., Coward, R. J., Fraser, D. J., & Bowen, T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114045 · Cited by 43 · see citing works
Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages
Bułdak, Ł., Łabuzek, K., Bułdak, R. J., Machnik, G., Bołdys, A., & Okopień, B. (2015) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-015-1124-3 · Cited by 41 · see citing works
Endogenous GLP-1 as a key self-defense molecule against lipotoxicity in pancreatic islets
HUANG, C., YUAN, L., & CAO, S. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2207 · Cited by 41 · see citing works
Lung ischemia reperfusion injury: the therapeutic role of dipeptidyl peptidase 4 inhibition
Beckers, P. A. J., Gielis, J. F., Schil, P. E. V., & Adriaensen, D. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.01.41 · Cited by 41 · see citing works
Liraglutide Protects Nucleus Pulposus Cells Against High-Glucose Induced Apoptosis by Activating PI3K/Akt/ mTOR/Caspase-3 and PI3K/Akt/GSK3β/Caspase-3 Signaling Pathways
Yao, M., Zhang, J., Zhi-hong, L., Bai, X., Ma, J., & Li, Y. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.630962 · Cited by 39 · see citing works
GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side
Dieter, B. P., Alicic, R. Z., & Tuttle, K. R. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00211.2018 · Cited by 38 · see citing works
A novel DPP-4 inhibitor teneligliptin scavenges hydroxyl radicals: In vitro study evaluated by electron spin resonance spectroscopy and in vivo study using DPP-4 deficient rats
Kimura, S., Inoguchi, T., Yamasaki, T., Yamato, M., Ide, M., Sonoda, N., Yamada, K., & Takayanagi, R. (2015) · Metabolism · doi:10.1016/j.metabol.2015.10.030 · Cited by 37 · see citing works
Self-citation
The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose
Salheen, S. M., Panchapakesan, U., Pollock, C. A., & Woodman, O. L. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.02.003 · Cited by 37 · see citing works
Glucagon-Like Peptide 1 Protects against Hyperglycemic-Induced Endothelial-to-Mesenchymal Transition and Improves Myocardial Dysfunction by Suppressing Poly(ADP-Ribose) Polymerase 1 Activity
Yan, F., Zhang, G.-H., Feng, M. H., Zhang, W., Zhang, J., Dong, W., Zhang, C., Zhang, Y., Chen, L., & Zhang, M.-X. (2015) · Molecular Medicine · doi:10.2119/molmed.2014.00259 · Cited by 37 · see citing works
Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
Mega, C., Teixeira‐Lemos, E., Fernandes, R., & Reis, F. (2017) · Journal of Diabetes Research · doi:10.1155/2017/5164292 · Cited by 37 · see citing works
GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials
Jia, X., Alam, M., Ye, Y., Bajaj, M., & Birnbaum, Y. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6773-2 · Cited by 37 · see citing works
Semaglutide Ameliorates Diabetic Neuropathic Pain by Inhibiting Neuroinflammation in the Spinal Cord
Lee, S.-O., Kuthati, Y., Huang, W.-H., & Wong, C. (2024) · Cells · doi:10.3390/cells13221857 · Cited by 39 · see citing works
Protein kinase C and protein kinase A are involved in the protection of recombinant human glucagon‐like peptide‐1 on glomeruli and tubules in diabetic rats
Yin, W., Jiang, Y., Xu, S., Wang, Z., Peng, L., Fang, Q., Deng, T., Zhao, W., Zhang, W., & Lou, J. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12956 · Cited by 33 · see citing works
Liraglutide ameliorates inflammation and fibrosis by downregulating the TLR4/MyD88/NF-κB pathway in diabetic kidney disease
Huang, L., Lin, T., Shi, M., & Wu, P. (2024) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00083.2024 · Cited by 33 · see citing works
GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies
Yang, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196758 · Cited by 37 · see citing works
Evaluation of the effects of liraglutide on the development of epilepsy and behavioural alterations in two animal models of epileptogenesis
Citraro, R., Iannone, M., Leo, A., Caro, C. D., Nesci, V., Tallarico, M., Abdalla, K., Palma, E., Arturi, F., Sarro, G. D., et al. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.08.001 · Cited by 33 · see citing works
Effect of combined therapy of mesenchymal stem cells with GLP-1 receptor agonist, exenatide, on early-onset nephropathy induced in diabetic rats
Habib, H. A., Heeba, G. H., & Khalifa, M. M. A. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173721 · Cited by 33 · see citing works
The effects of glucagon-like peptide-1 receptor agonists and dipeptydilpeptidase-4 inhibitors on blood pressure and cardiovascular complications in diabetes
Yaribeygi, H., Farrokhi, F. R., Abdalla, M. A., Sathyapalan, T., Banach, M., Jamialahmadi, T., & Sahebkar, A. (2021) · Journal of Diabetes Research · doi:10.1155/2021/6518221 · Cited by 31 · see citing works
Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies
Petersen, K. E., Rakipovski, G., Raun, K., & Lykkesfeldt, J. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666150918150608 · Cited by 33 · see citing works
Mechanisms and clinical applications of incretin therapies for diabetes and chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000894 · Cited by 31 · see citing works
Protective effects of glucagon‐like peptide‐1 on cardiac remodeling by inhibiting oxidative stress through mammalian target of rapamycin complex 1/p70 ribosomal protein S6 kinase pathway in diabetes mellitus
Wang, D., Jiang, L., Feng, B., He, N., Zhang, Y., & Ye, H. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13098 · Cited by 31 · see citing works
Renal protection with glucagon-like peptide-1 receptor agonists
Vitale, M., Haxhi, J., Cirrito, T., & Pugliese, G. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.08.018 · Cited by 31 · see citing works

The impact of the glucagon-like peptide 1 receptor agonist liraglutide on the streptozotocin-induced diabetic mouse kidney proteome
Liljedahl, L., Pedersen, M. H., McGuire, J. N., & James, P. (2019) · Physiological Reports · doi:10.14814/phy2.13994 · Cited by 21 · see citing works
The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential
Fujita, H., Morii, T., Fujishima, H., Sato, T., Shimizu, T., Hosoba, M., Tsukiyama, K., Narita, T., Takahashi, T., Drucker, D. J., et al. (2014) · Kidney International · doi:10.1038/ki.2013.427 · Cited by 336 · see citing works
GLP ‐1 receptor agonist liraglutide alleviates kidney injury by regulating nuclear translocation of NRF2 in diabetic nephropathy
Lin, T., Zhang, Y., Wei, Q., & Huang, Z. (2024) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.70003 · Cited by 5 · see citing works
Liraglutide ameliorates early renal injury by the activation of renal FoxO1 in a type 2 diabetic kidney disease rat model
Chen, P., Shi, X., Xu, X., Lin, Y., Shao, Z., Wu, R., & Huang, L. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.09.006 · Cited by 45 · see citing works
Reno-Protective Effect of GLP-1 Receptor Agonists in Type1 Diabetes: Dual Action on TRPC6 and NADPH Oxidases
Youssef, N., Noureldein, M. H., Njeim, R., Ghadieh, H. E., Harb, F., Azar, S. T., Farès, N., & Eid, A. A. (2021) · Biomedicines · doi:10.3390/biomedicines9101360 · Cited by 22 · see citing works

Authors: Hendarto, H., Inoguchi, T., Maeda, Y., Ikeda, N., Zheng, J., Takei, R., Yokomizo, H., Hirata, E., Sonoda, N., & Takayanagi, R.
Affiliations: Kyushu University (JP)
Corresponding author: Inoguchi, Toyoshi
ORCID: Hendarto, Hari
Inoguchi, Toyoshi
Maeda, Yasutaka
Ikeda, Noriko
Zheng, Jing
Yokomizo, Hisashi
Sonoda, Noriyuki
Venue: Metabolism
Publisher: Elsevier BV
Published: 2012-10
Volume: 61
Issue: 10
Pages: 1422-1434
ISSN: 0026-0495 (ISSN-L)
DOI: 10.1016/j.metabol.2012.03.002
OpenAlex: W1983883248
Cited by: 232
References: 43
Citations by year: 2026: 7 · 2025: 17 · 2024: 20 · 2023: 16 · 2022: 8 · 2021: 17 · 2020: 21 · 2019: 21 · 2018: 18 · 2017: 15 · 2016: 16 · 2015: 19 · 2014: 14 · 2013: 18 · 2012: 4
FWCI: 13.96
Type: journal article
Language: en
Open access: green
repository.uinjkt.ac.id
Licence: cc-by-nc
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Metabolism (publishedVersion)
PubMed (publishedVersion)
Universitas Islam Negeri Syarif Hidayatullah Institutional Repository (Universitas Islam Negeri Syarif Hidayatullah Jakarta) (submittedVersion, cc-by-nc)
Funders: Japan Society for the Promotion of Science (23390247)
Topics: Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
Keywords: liraglutide, GLP-1 analogues, diabetic nephropathy, oxidative stress, albuminuria, protein kinase A, NADPH oxidase, type 1 diabetes, streptozotocin-induced diabetes, renal mesangial cells, superoxide production, TGF-beta, fibronectin, Epac2, renal fibrosis
MeSH terms: Liraglutide, Adenine, Albuminuria, Animals, Cells, Cultured, Diabetes Mellitus, Experimental, Diabetic Nephropathies, Humans, Isoquinolines, Kidney, Male, Multienzyme Complexes, NADH, NADPH Oxidoreductases, Streptozocin, Sulfonamides, Rats, Wistar, Cyclic AMP-Dependent Protein Kinases, Oxidative Stress, Rats, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks